These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vancomycin assay performance in patients with acute renal failure. Trujillo TN; Sowinski KM; Venezia RA; Scott MK; Mueller BA Intensive Care Med; 1999 Nov; 25(11):1291-6. PubMed ID: 10654216 [TBL] [Abstract][Full Text] [Related]
3. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Follin SL; Mueller BA; Scott MK; Carfagna MA; Kraus MA Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140 [TBL] [Abstract][Full Text] [Related]
4. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. Peckman HJ; Dupuis RE; Sawyer WT; Brouwer KL; Cross RE Ther Drug Monit; 1996 Dec; 18(6):647-53. PubMed ID: 8946660 [TBL] [Abstract][Full Text] [Related]
5. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Smith PF; Petros WP; Soucie MP; Copeland KR Ther Drug Monit; 1998 Apr; 20(2):231-5. PubMed ID: 9558140 [TBL] [Abstract][Full Text] [Related]
6. Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure. Saunders NJ; Want SV; Adams DJ J Antimicrob Chemother; 1995 Aug; 36(2):411-5. PubMed ID: 8522471 [TBL] [Abstract][Full Text] [Related]
7. Underestimation of rat serum vancomycin concentrations measured by an enzyme-multiplied immunoassay technique and the strategy for its avoidance. Konishi H; Iga I; Nagai K Drug Test Anal; 2014 Apr; 6(4):350-6. PubMed ID: 23943307 [TBL] [Abstract][Full Text] [Related]
8. Effects of dialysis membrane on intradialytic vancomycin administration. Scott MK; Macias WL; Kraus MA; Clark WR; Carfagna MA; Mueller BA Pharmacotherapy; 1997; 17(2):256-62. PubMed ID: 9085316 [TBL] [Abstract][Full Text] [Related]
9. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure? Sym D; Smith C; Meenan G; Lehrer M Ther Drug Monit; 2001 Aug; 23(4):441-4. PubMed ID: 11477330 [TBL] [Abstract][Full Text] [Related]
10. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Somerville AL; Wright DH; Rotschafer JC Pharmacotherapy; 1999 Jun; 19(6):702-7. PubMed ID: 10391415 [TBL] [Abstract][Full Text] [Related]
11. Interference with vancomycin fluorescence polarisation immunoassay in a nonuraemic patient. Bowhay S; Timms P Ther Drug Monit; 1997 Feb; 19(1):117-9. PubMed ID: 9029761 [TBL] [Abstract][Full Text] [Related]
12. Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies. Azzazy HM; Chou PP; Tsushima JH; Troxil S; Gordon M; Avers RJ; Chiappetta E; Duh SH; Christenson RH Ther Drug Monit; 1998 Apr; 20(2):202-8. PubMed ID: 9558135 [TBL] [Abstract][Full Text] [Related]
13. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. Morishige H; Shuto H; Ieiri I; Otsubo K; Oishi R Ther Drug Monit; 1996 Feb; 18(1):80-5. PubMed ID: 8848826 [TBL] [Abstract][Full Text] [Related]
14. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. Najjar TA; al-Dhuwailie AA; Tekle A J Chromatogr B Biomed Appl; 1995 Oct; 672(2):295-9. PubMed ID: 8581137 [TBL] [Abstract][Full Text] [Related]
15. Vancomycin monitoring in term newborns: comparison of peak and trough serum concentrations determined by high performance liquid chromatography and fluorescence polarization immunoassay. Feferbaum R; Kobol Machado JK; de Albuquerque Diniz EM; Okay TS; Santos SR; Ceccon ME; Krebs VL; de Araújo MC; Costa Vaz A Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(5):149-52. PubMed ID: 11781595 [TBL] [Abstract][Full Text] [Related]
17. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Morse GD; Nairn DK; Bertino JS; Walshe JJ Ther Drug Monit; 1987 Jun; 9(2):212-5. PubMed ID: 3617161 [TBL] [Abstract][Full Text] [Related]
18. Competitive immunoassay for vancomycin using capillary electrophoresis with laser-induced fluorescence detection. Lam MT; Le Chris X Analyst; 2002 Dec; 127(12):1633-7. PubMed ID: 12537372 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347 [TBL] [Abstract][Full Text] [Related]
20. More information on vancomycin clearance by new hemodialysis membranes. Mueller BA; Scott MK; Clark WR Am J Health Syst Pharm; 1996 Jun; 53(11):1339-40, 1348. PubMed ID: 8725212 [No Abstract] [Full Text] [Related] [Next] [New Search]